Study protocol on azelastine.
Kelso
J M
JM
D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D002744:Chlorpheniramine / Q000627:therapeutic use*; D003627:Data Interpretation, Statistical; D004311:Double-Blind Method; D004358:Drug Therapy / Q000191:economics; D064420:Drug-Related Side Effects and Adverse Reactions; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D010793:Phthalazines / Q000008:administration & dosage / Q000627:therapeutic use*; D012107:Research Design; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D018401:Sample Size; D014481:United States; D014486:United States Food and Drug Administration
D018926:Anti-Allergic Agents; D006634:Histamine H1 Antagonists; D010793:Phthalazines; D002744:Chlorpheniramine; C020976:azelastine